Diabetes & metabolic syndrome
-
Diabetes Metab Syndr · Apr 2017
Metabolic syndrome and C reactive protein in patients undergoing angiography: Inevitable association?
The Metabolic Syndrome (MS) is characterized by a set of risk factors, which causes metabolic and inflammatory changes that increase vascular risk and may promote the development of atherosclerosis. Changes in lifestyle are related to obesity and associated diseases such as hypertension, type 2 diabetes mellitus, MS and cardiovascular disease (CVD). ⋯ We may say that the improvement of the above parameters could reduce inflammation and oxidative stress and vascular damages what would extend life expectancy and quality of life of this group of patients.
-
Diabetes Metab Syndr · Jan 2017
ReviewThe effect of Ramadan fasting on glycaemic control in insulin dependent diabetic patients: A literature review.
Ramadan fasting is one of the five pillars of Islam. People with diabetes are exempted from fasting according to Islamic rules. However, many people with diabetes wish to fast. Physicians are asked frequently by their patients about their ability to fast and the possible impact of fasting on their glycaemic control. Studies about the effect of Ramadan on people with insulin-treated diabetes are scarce. This review aims to provide clinicians with the best recommendations for their patients with insulin-treated diabetes who wish to fast. ⋯ Ramadan fasting is feasible for insulin dependent diabetic patient who wish to fast. Clinicians should advise their patients about the importance of adequate glycaemic control before Ramadan and frequent glucose monitoring during fasting. Certain types of Insulin seem to be more beneficial than other.
-
Diabetes Metab Syndr · Jul 2016
Comparative StudyInsulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India.
To compare the changes in various glycemic parameters in insulin-naïve type 2 diabetes mellitus (DM) patients who were initiated on insulin glargine or insulin degludec in a real world setting. ⋯ Results from this real world analysis suggest that among type 2 DM patients who were initiated on insulin degludec as compared to insulin glargine may be associated with significantly lesser patient reported hypoglycemic episodes and lesser dose of insulin while achieving similar glycemic control. This study is however limited by the retrospective nature of the data collection.
-
Diabetes Metab Syndr · Jan 2016
Randomized Controlled Trial Comparative StudyA comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
This study was done to illustrate the clinical and biochemical effects of ethinyl estradiol-cyproterone acetate (EE-AC) and metformin in this disease. ⋯ This study showed that metformin treatment is beneficial in improving serum lipids; glucose homeostasis and BMI, however, the ethinyl estradiol-cyproterone acetate is superior in improving the clinical manifestation of patients with PCOS, including menstrual cycle regulation, hyperandrogenic state.
-
Diabetes Metab Syndr · Jan 2016
Glycemic and non-glycemic targets in younger and older North Indian subjects with type 2 diabetes in a Tertiary care hospital: A 10 year's retrospective data analysis.
Although optimizing glycemic and non-glycemic targets reduced micro- and macro-vascular complications in type 2 diabetes, multiple barriers hinder turning evidence into practice. Mounting evidence suggests that those with onset of disease in early or mid-adult life, compared with those with onset at an older age, may have a more severe disease course and worse glycemic control. ⋯ Younger age (<60 years) at type 2 diabetes diagnosis is significantly associated with worse subsequent glycemic control and lipid control, as younger patients at diagnosis have fewer competing co-morbidities and complications. As patient-centeredness is a priority in type 2 diabetes care, safe, aggressive and individualized treatment could benefit this higher-risk group.